(Reuters) -German biotech firm Evotec SE said on Tuesday it would seek a valuation of about $9.2 billion in its initial public offering in the United States.
The company has a market capitalization of $8.3 billion on the Frankfurt Stock Exchange, where its shares are already listed, according to Refinitiv data.
Founded in 1993, Hamburg-headquartered Evotec offers a suite of technologies that enable faster and cheaper drug discoveries by pharmaceutical companies.
The company last year received a grant from the Bill & Melinda Gates Foundation to help identify and develop potential monoclonal antibody drugs for the prevention of severe COVID-19.
Evotec said in its filing that it would look to raise up to $575.5 million in the IPO by offering 22 million American depositary shares (ADSs) at $26.16 each. Each ADS represents one-half of an ordinary share.
BofA Securities and Morgan Stanley are the lead underwriters for the offering.
Reporting by Niket Nishant in Bengaluru; Editing by Krishna Chandra Eluri and Aditya Soni
Our Standards: The Thomson Reuters Trust Principles.